Studying the immune response in non-cancer-spread breast surgery
Part of Cancer, Skin clinical trials.
This study looks at how your immune system changes while you receive standard breast cancer treatment around the time of surgery. The goal is to learn why some people respond better than others, which could help future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman age 18 or older
- You have breast cancer that has not spread to distant organs (non-metastatic)
- Your treatment plan includes breast surgery (surgical removal of the tumor)
- The surgery and care must be through the University of Pennsylvania Health System
- You must be able to participate as part of the surgical treatment process (study visits or samples may be involved)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with breast cancer and certain lymphomas to understand long-term sexual and reproductive health. It may help researchers better support patients’ body changes and wellness over time during and after treatment.
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
This study looks at how the immune system changes in people with breast cancer, using patient tissue samples. It may help researchers understand immune responses in young women and guide future cancer treatments.
This study looks at how breast cancer changes while you are receiving chemotherapy or targeted therapy before surgery. The goal is to better understand which treatments work best for different types of breast cancer.
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.